SCHEMBL6091297

SCHEMBL6091297

O=C(O)c1ccc(C(=O)Cc2cc(-c3cccs3)ccc2OCCN2CCCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
ESR1 P03372 2/20 0.45
ESR2 Q92731 2/20 0.45
MCHR1 Q99705 5/20 0.44
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DRD2 P14416 2/20 0.41
DRD1 P21728 2/20 0.41
DRD3 P35462 2/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
TBK1 Q9UHD2 1/20 0.40
HRH1 P35367 2/20 0.40
ABCB1 P08183 1/20 0.40
DRD4 P21917 1/20 0.40
DRD5 P21918 1/20 0.40
LTA4H P09960 1/20 0.40
PSMB1 P20618 1/20 0.39
PSMB5 P28074 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092970 0.90 KDM4E (0.48) KCNH2HRH3ESR1ESR2MCHR1
SCHEMBL6092917 0.85 SMN1; SMN2 (0.43) SMN1; SMN2
SCHEMBL6092988 0.82 KCNH2 (0.45) KCNH2HRH3ESR1ESR2MCHR1
Hydrochloric Acid SCHEMBL6092915 0.81 KCNH2 (0.45) KCNH2HRH3ESR1ESR2MCHR1
SCHEMBL6109578 0.80 LTA4H (0.44) LTA4H
SCHEMBL6091940 0.79 TNFRSF1A (0.52) KDM4E
SCHEMBL6091879 0.76 RXRA (0.45) KDM4E
SCHEMBL6094179 0.76 HRH3 (0.56) KCNH2HRH3ESR1ESR2MCHR1
SCHEMBL6092086 0.76 SMN1; SMN2 (0.46) SMN1; SMN2
SCHEMBL6094350 0.75 TNFRSF1A (0.45) KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ATHEROGENICS, INC. 2006-03-23 US disclosed
WO-2006004903-A2 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF ATHEROGENICS, INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063828-A1 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof ABCB11, CEL, CYP46A1 KCNH2 1511/4885HRH3 1814/4885ESR1 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.